Login to Your Account

Pharma: Other news to note

Tuesday, December 10, 2013
Helsinn Group, of Lugano, Switzerland, and Eisai Inc., of Woodcliff Lake, N.J., said the FDA accepted for review the submission of the new drug application for the investigational oral fixed-dose combination capsule of netupitant 300 mg + palonosetron 0.50 mg for prevention of acute and delayed chemotherapy-induced nausea and vomiting following highly and moderately emetogenic chemotherapy.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription